Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.
HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.
Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia,.
French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
HQ Team July 16, 2024: A new animal study has found a new therapy that is able to boost inuslin-producing cells by 700%.
Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.
Research finds a sharp increase in use of weightloss drugs such as Ozempic and Wegovy among teens and young adults
HQ Team March 21, 2024: Richard Slayman, 62, of Weymouth, Massachusetts, became the first human to receive a kidney from a genetically modified.